Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report
Open Access
- 31 May 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Medical Case Reports
- Vol. 15 (1), 1-4
- https://doi.org/10.1186/s13256-021-02858-7
Abstract
Immune checkpoint inhibitors are effective therapies for a wide range of malignancies. Their increased use has led to a wide range of immune-related adverse effects including skin, gastrointestinal, pulmonary, endocrine, cardiac, and neurologic complications. We present the case of a 72-year-old Caucasian man with non-small cell lung cancer who was admitted for dyspnea after two cycles of durvalumab. He was found to have significantly elevated levels of serum creatinine kinase and troponin with a negative cardiac catheterization. During his hospitalization, he developed progressive dyspnea and new-onset axial weakness, ultimately leading to the diagnosis of durvalumab-induced myocarditis, myasthenia gravis, and myositis. This is, to our knowledge, the first reported case of anti-programmed cell death ligand 1-induced combination of myocarditis, myasthenia gravis, and myositis. While the use of immunologic agents has resulted in overall improved cancer outcomes, their increased use has led to a vast spectrum of immune-related adverse effects. We review the diagnostic workup and management of patients with these immune-related adverse effects, underscoring the importance of early identification given the potential for rapid deterioration.This publication has 12 references indexed in Scilit:
- Immune Checkpoint Inhibitor-Induced Myasthenia GravisFrontiers in Neurology, 2020
- Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and TreatmentJournal of the American Heart Association, 2020
- Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literatureJournal for ImmunoTherapy of Cancer, 2019
- Factors Associated With Immune Checkpoint Inhibitor–Related MyocarditisJAMA Oncology, 2019
- Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemiaAnnals of Clinical and Translational Neurology, 2018
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2018
- Nivolumab-related myasthenia gravis with myositis and myocarditis in JapanNeurology, 2017
- Myasthenia Gravis-Like Syndrome Presenting as a Component of the Paraneoplastic Syndrome of Lung Adenocarcinoma in a NonsmokerCase Reports in Oncological Medicine, 2014
- Muscle autoantibodies in myasthenia gravis: beyond diagnosis?Expert Review of Clinical Immunology, 2012
- Autoimmune Targets of Heart and Skeletal Muscles in Myasthenia GravisArchives of Neurology, 2009